Results 91 to 100 of about 4,251 (181)

Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results

, 2020
Therapeutic targeting of Bruton tyrosine kinase (BTK) has dramatically improved survival outcomes for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Wierda W. G., Woyach J. A., Ghia P., Barrientos J., Chaves J. M., Awan F. T., Hamdy A., Rothbaum W., Byrd J. C., Hillmen P., Devereux S., Martin P., Izumi R., Patel P., Stephens D. M., Wang M. H., Frigault M. M., Schuh A., Gulrajani M., O'Brien S., Burke K., Furman R. R., Pagel J. M., Covey T., Brown J. R.   +24 more
core   +1 more source

Acalabrutinib [PDF]

Reactions Weekly, 2020
  +4 more sources

Bruton’s tyrosine kinase inhibition limits endotoxic shock by suppressing IL-6 production by marginal zone B cells in mice

Frontiers in Immunology
Sepsis is a systemic inflammatory response to a severe, life-threatening infection with organ dysfunction. Although there is no effective treatment for this fatal illness, a deeper understanding of the pathophysiological basis of sepsis and its ...
Kazuhiko Kawata, Shinya Hatano, Akemi Baba, Keisuke Imabayashi, Yoshihiro Baba   +4 more
doaj   +1 more source

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Process for the Preparation of Crystalline Acalabrutinib Maleate Monohydrate

Process for the Preparation of Crystalline Acalabrutinib Maleate Monohydrate Acalabrutinib or 4-{8-Amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1- yl}-N-(pyridin-2-yl)benzamide is the active pharmaceutical ingredient (API) in the ...
Anonymous,
core  

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Efficacy and safety of BTK inhibitors in Richter’s transformation: a systematic review of clinical evidence

Frontiers in Oncology
BackgroundRichter’s transformation (RT) is an aggressive progression of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), most commonly to diffuse large B-cell lymphoma (DLBCL). Therapeutic options are limited, and outcomes are poor,
Canan D. Dirican, Folasade Ajayi, Anas Al Mardini, Bolivia Crocete Aloysia Fernandes, Amara Sofia, Venkatesh Gondhi, Hamid Shaaban, Michael Maroules   +7 more
doaj   +1 more source

Current Therapeutic Sequencing in Chronic Lymphocytic Leukemia

Hematology Reports
The treatment landscape of chronic lymphocytic leukemia (CLL), the most frequent leukemia in adults, is constantly changing. CLL patients can be divided into three risk categories, based on their IGHV mutational status and the occurrence of TP53 ...
Samir Mouhssine, Nawar Maher, Sreekar Kogila, Claudio Cerchione, Giovanni Martinelli, Gianluca Gaidano   +5 more
doaj   +1 more source

Aplastic anemia triggered by the Bruton tyrosine kinase inhibitor acalabrutinib in two patients with mantle cell lymphoma – A case report

eJHaem
The use of Bruton's tyrosine kinase inhibitors (BTKi) is rapidly increasing for patients with mantle cell lymphoma (MCL). Side effects reported so far are usually manageable.
Anna Nikkarinen, Ingrid Glimelius
doaj   +1 more source

Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.

, 2019
The Bruton tyrosine kinase (BTK) inhibitor ibrutinib improves patient outcomes in chronic lymphocytic leukemia (CLL); however, some patients experience adverse events (AEs) leading to discontinuation.
Pagel, John M, Patel, Priti, Woyach, Jennifer, Bibikova, Elena, Byrd, John C, Brown, Jennifer R, Wang, Min Hui, Frigault, Melanie M, Charuworn, Prista, Furman, Richard R, Awan, Farrukh T, Hillmen, Peter, Hamdy, Ahmed, Izumi, Raquel, Stephens, Deborah M, Linghu, Bolan, Schuh, Anna   +16 more
core